Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indication.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Archives of Dermatology

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/archderm.144.5.683PMID 18490603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial.

  2006cited by this paper
• Heat Shock Protein 10 Inhibits Lipopolysaccharide-induced Inflammatory Mediator Production*

  2005cited by this paper
• An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

  2003cited by this paper
• Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity.

  2000influential reference

• Therapeutic Potential of Heat Shock Proteins in Human Inflammation/Autoimmune Skin Diseases: Future Directions

  2020cites this paper
• Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review.

  2020cites this paper
• Çok işlevli Proteinler: Moonlight Proteinler

  2020cites this paper
• Extracellular cell stress (heat shock) proteins—immune responses and disease: an overview

  2018cites this paper
• Early pregnancy factor, chaperonin 10 and rheumatoid arthritis; the story unravels

  2018cites this paper
• Results of a phase IIa clinical trial of an anti-inflammatory molecule , chaperonin 10 , in multiple sclerosis

  2017cites this paper
• Results of a phase IIa clinical trial of an endogenous anti-inflammatory molecule , chaperonin 10 , in multiple sclerosis

  2017cites this paper
• Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood.

  2016cites this paper
• Production and characterisation of recombinant human chaperonin 10 for treatment of inflammatory disease

  2015cites this paper
• Multitasking Bacterial Moonlighting Proteins in Bacterial Virulence and Infectious Disease

  2014cites this paper
• Early-forming aberrant aggregates in protein deposition diseases: structural characteristics, interaction with molecular chaperones, ability to trigger inflammation

  2013cites this paper
• Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis

  2013cites this paper
• Monocyte cytokine synthesis in response to extracellular cell stress proteins suggests these proteins exhibit network behaviour

  2013cites this paper
• Hsp10: anatomic distribution, functions, and involvement in human disease.

  2013cites this paper
• Chaperonin 10, a Pro- and Anti-inflammatory Host Modulator

  2013cites this paper
• Bacterial moonlighting proteins and bacterial virulence.

  2013cites this paper
• Pro-resolution immunological networks: binding immunoglobulin protein and other resolution-associated molecular patterns.

  2012cites this paper
• Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice.

  2012cites this paper
• Current and Emerging Systemic Treatment Strategies for Psoriasis

  2012cites this paper
• Moonlighting is mainstream: Paradigm adjustment required

  2012cites this paper
• A New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP?

  2012cites this paper
• Biotech on the Rise: The Treatment of Psoriasis with Biological Drugs

  2012cites this paper
• Molecular Chaperones and Protein-Folding Catalysts in Biological Fluids

  2012cites this paper
• Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy

  2011cites this paper
• Resolution‐associated molecular patterns (RAMP): RAMParts defending immunological homeostasis?

  2011cites this paper
• Psoriasis Treatments: A Review of the Current Research Pipeline

  2011cites this paper
• Results of a phase IIa clinical trial of an endogenous anti-inflammatory molecule , chaperonin 10 , in multiple sclerosis

  2010cites this paper
• Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants

  2010cites this paper
• Molecular chaperones and protein‐folding catalysts as intercellular signaling regulators in immunity and inflammation

  2010cites this paper
• Chaperonin 10 as an endothelial‐derived differentiation factor: Role of glycogen synthase kinase‐3

  2009cites this paper
• Sexual dimorphism in autoimmune disease.

  2009cites this paper
• Emerging drugs for psoriasis

  2009cites this paper
• Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis

  2009cites this paper